COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) AFTER THE FAILURE OF A FIRST TNF INHIBITOR IN THE UNITED KINGDOM

被引：0
|
作者：
Pericleous, L. [1 ]
Lebmeier, M. [2 ]
机构：
[1] Bristol Myers Squibb Pharmaceut, Uxbridge, Middx, England
[2] Bristol Myers Squibb, Uxbridge, Middx, England
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 07期
关键词：
D O I：
10.1016/j.jval.2011.08.417
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A307 / A308
页数：2
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN SPAIN
    Guijarro, P.
    Crespo, C.
    Brosa, M.
    VALUE IN HEALTH, 2012, 15 (07) : A448 - A448
  • [22] Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States
    Claxton, Lindsay
    Taylor, Matthew
    Gerber, Robert A.
    Gruben, David
    Moynagh, Dermot
    Singh, Amitabh
    Wallenstein, Gene, V
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (11) : 1991 - 2000
  • [23] Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
    Sofie HM Manders
    Wietske Kievit
    Eddy Adang
    Herman L Brus
    Hein J Bernelot Moens
    Andre Hartkamp
    Lidy Hendriks
    Elisabeth Brouwer
    Henk Visser
    Harald E Vonkeman
    Jos Hendrikx
    Tim L Jansen
    Rene Westhovens
    Mart AFJ van de Laar
    Piet LCM van Riel
    Arthritis Research & Therapy, 17
  • [24] Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor
    Finckh, Axel
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2012, 1 (06) : 481 - 484
  • [25] Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
    Manders, Sofie H. M.
    Kievit, Wietske
    Adang, Eddy
    Brus, Herman L.
    Moens, Hein J. Bernelot
    Hartkamp, Andre
    Hendriks, Lidy
    Brouwer, Elisabeth
    Visser, Henk
    Vonkeman, Harald E.
    Hendrikx, Jos
    Jansen, Tim L.
    Westhovens, Rene
    van de Laar, Mart A. F. J.
    van Riel, Piet L. C. M.
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [26] COST-EFFECTIVENESS OF TOCILIZUMAB FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS (RA) PATIENTS WITH INADEQUATE RESPONSE TO ANTI-TNF TREATMENT IN TURKEY
    Ertenli, I
    VALUE IN HEALTH, 2012, 15 (07) : A445 - A445
  • [27] INVESTIGATING THE VALUE OF ABATACEPT IV IN THE TREATMENT OF RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS STUDIES
    Athanasakis, K.
    Petrakis, I
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A563 - A563
  • [28] AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO A TUMOUR NECROSIS FACTOR INHIBITOR IN CANADA
    Yunger, S.
    Mistry, B.
    VALUE IN HEALTH, 2009, 12 (03) : A70 - A70
  • [29] Cost-effectiveness analyses of TNF antagonists in rheumatoid arthritis: A review
    Bansback, N
    Regier, D
    Ara, R
    Brenan, A
    Shojania, K
    Esdaile, J
    Anis, A
    Marra, C
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S510 - S510
  • [30] COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
    Gossec, L.
    Goupille, P.
    Saraux, A.
    Bregman, B.
    Boccard, E.
    Dupont, D.
    Beresniak, A.
    VALUE IN HEALTH, 2008, 11 (06) : A542 - A543
12345